Ryvu Therapeutics 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Pawel Przewiezlikowski

최고 경영자

zł1.1m

총 보상

CEO 급여 비율	78.4%
CEO 임기	no data
CEO 소유권	17.4%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	5.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Pawel Przewiezlikowski 의 보수는 Ryvu Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-zł104m
Jun 30 2024	n/a	n/a	-zł96m
Mar 31 2024	n/a	n/a	-zł94m
Dec 31 2023	zł1m	zł838k	-zł92m
Sep 30 2023	n/a	n/a	-zł73m
Jun 30 2023	n/a	n/a	-zł66m
Mar 31 2023	n/a	n/a	-zł75m
Dec 31 2022	zł341k	zł165k	-zł84m
Sep 30 2022	n/a	n/a	-zł94m
Jun 30 2022	n/a	n/a	-zł105m
Mar 31 2022	n/a	n/a	-zł92m
Dec 31 2021	zł1m	n/a	-zł79m
Sep 30 2021	n/a	n/a	-zł72m
Jun 30 2021	n/a	n/a	-zł61m
Mar 31 2021	n/a	n/a	-zł41m
Dec 31 2020	n/a	n/a	-zł32m
Sep 30 2020	n/a	n/a	-zł40m
Jun 30 2020	n/a	n/a	-zł32m
Mar 31 2020	n/a	n/a	-zł41m
Dec 31 2019	zł524k	zł524k	-zł44m
Sep 30 2019	n/a	n/a	-zł53m
Jun 30 2019	n/a	n/a	-zł60m
Mar 31 2019	n/a	n/a	-zł28m
Dec 31 2018	zł476k	zł476k	-zł23m
Sep 30 2018	n/a	n/a	zł2m
Jun 30 2018	n/a	n/a	zł14m
Mar 31 2018	n/a	n/a	zł21m
Dec 31 2017	zł655k	zł655k	zł6m

보상 대 시장: Pawel 의 총 보상 ($USD 260.14K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 782.05K ).

보상과 수익: 회사가 수익성이 없는 동안 Pawel 의 보상이 증가했습니다.

CEO

Pawel Przewiezlikowski

no data

테뉴어

zł1,068,120

보상

Mr. Pawel Tadeusz Przewiezlikowski, MSc., MBA, serves as the Chief Executive Officer of BioCentrum Sp. z o.o. Mr. Przewiezlikowski serves as a Member of Supervisory Board of SELVITA S.A.Mr. Przewiezlikow...

리더십 팀

이름	위치	테뉴어	보상	소유권
Pawel Przewiezlikowski	Founder	no data	zł1.07m	17.44% € 42.1m
Krzysztof Brzózka	Executive VP	12.8yrs	zł1.43m	1.16% € 2.8m
Kamil Sitarz	COO & Member of the Management Board	4yrs	zł1.18m	0.17% € 409.7k
Vatnak Vat-Ho	Chief Business Officer & Member of Management Board	2.3yrs	zł2.22m	0.18% € 446.4k
Hendrik Nogai	Chief Medical Officer & Member of Management Board	2.3yrs	zł2.17m	0.058% € 141.0k
Paulina Wolanin	Human Resources Manager	no data	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

경험이 풍부한 관리: 9Y4 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Peter Smith	Member of Supervisory Board	1.4yrs	zł90.15k	데이터 없음
Rafal Chwast	Independent Member of the Supervisory Board	no data	zł159.99k	0.52% € 1.3m
Tadeusz Wesolowski	Non-Independent Vice Chairman of Supervisory Board	no data	zł157.23k	0.40% € 970.9k
Scott Fields	Member of Supervisory Board	1.4yrs	zł121.27k	데이터 없음
Piotr Romanowski	Independent Chairman of the Supervisory Board	13.8yrs	zł159.78k	0.22% € 522.1k
Axel Glasmacher	Non-Independent Member of the Supervisory Board	5.2yrs	zł157.23k	데이터 없음
Thomas Turalski	Non-Independent Member of the Supervisory Board	5.2yrs	zł157.23k	0.087% € 209.9k

5.2yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: 9Y4 의 이사회는 경험(평균 재직 기간 5.2 년)으로 간주됩니다.

Ryvu Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Ryvu Therapeutics S.A., Annual General Meeting, Jun 27, 2024

Ryvu Therapeutics S.A., Annual General Meeting, Jun 14, 2023

Ryvu Therapeutics Announces Executive Changes

Ryvu Therapeutics S.A., Annual General Meeting, Jun 30, 2022

Recent updates

Third quarter 2024 earnings released: zł1.10 loss per share (vs zł0.79 loss in 3Q 2023)

Ryvu Therapeutics Announces Dosing of the First Patient in the Remark Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

New major risk - Financial position

Second quarter 2024 earnings released: zł1.40 loss per share (vs zł1.23 loss in 2Q 2023)

Ryvu Therapeutics S.A., Annual General Meeting, Jun 27, 2024

New major risk - Financial position

Full year 2023 earnings released: zł3.98 loss per share (vs zł4.56 loss in FY 2022)

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml

Ryvu Therapeutics S.A. to Report Q1, 2024 Results on May 15, 2024

Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023

Third quarter 2023 earnings released

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

Second quarter 2023 earnings released

Ryvu Therapeutics S.A., Annual General Meeting, Jun 14, 2023

First quarter 2023 earnings released

Ryvu Therapeutics S.A. to Report Q3, 2023 Results on Nov 29, 2023

Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics S.A. Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Ryvu Therapeutics S.A. announced that it expects to receive PLN 1.9 million in funding

Ryvu Therapeutics S.A. announced that it has received €22 million in funding from European Investment Bank, Investment Arm

Ryvu Therapeutics Announces Executive Changes

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics S.A., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: zł1.45 loss per share (vs zł0.74 loss in 1Q 2021)

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 At the 2022 European Hematology Association Congress

Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology Annual Meeting

Full year 2021 earnings: Revenues exceed analyst expectations

Ryvu Therapeutics S.A. Presents Clinical and Translational Data Updates At the 63rd American Society of Hematology Annual Meeting and the 44Th San Antonio Breast Cancer Symposium

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Ryvu Therapeutics S.A. Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors

Ryvu Therapeutics S.A. Announces FDA Lifts Partial Clinical Hold on Phase IB Clinical Trial of RVU120 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Ryvu Therapeutics Presents Positive Phase I Data for Rvu120 of Phase I/Ii Data for Sel24 Presented by Development Partner Menarini

Ryvu Therapeutics Announces Results SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

Ryvu Therapeutics S.A. Got Full Approval to Conduct Phase I/Ii Study of Rvu120 (Sel120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors in Poland

First quarter 2021 earnings released

Ryvu Therapeutics S.A. to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association

Full year 2020 earnings released

Ryvu Signs a Deal for Phase I Clinical Trials for its RVU120 Drug

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령